Stockreport

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio, Inc.  (TRML) 
PDF – On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB) [Read more]